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THE Epstein-Barr virus, also called "The Kissing Virus", is perhaps the commonest
of all viruses that infect human beings. It usually causes no ill-effects whatsoever,
but it does cause glandular fever or infectious mononucleosis, and there is
substantial evidence linking it with two human cancers, not usually found in this
part of the world. It was discovered through the co-operation of surgeons,
physicians and pathologists and is involved in many branches of medicine. In recent
years it has been implicated in a wide variety of clinical conditions.
This virus belongs to the Herpesvirus Group, and while each member ofthe group
has absolutely similar appearance when examined by the electron microscope, each
is distinguishable by the different disease or diseases which it causes and by the
different antibodies which it produces. For instance, herpes simplex causes cold
sores, varicella zoster causes chicken pox and shingles, and cytomegalovirus causes
both congenital infection and infection in renal transplant patients. Epstein-Barr
(EB) virus causes glandular fever, an acute and self limited disease usually in young
adults, which is associated with severe fatigue and which can last for up to six weeks.
The main symptoms are skin rash, pharyngitis, tonsillitis, enlarged lymph glands
and enlarged spleen, and the peak incidence of the illness is around twenty years of
age. Convalescence can be prolonged, and relapses and complications are both rare.
Diagnosis is made clinically and by examination of the blood, which initially shows a
diminished number of white blood cells, followed by a striking increase in their
number with a large proportion of mononuclear cells, some of which are atypical
1lymphocytes. These cells have a hyperbasophilic and vacuolated cytoplasm, and
kidney shaped nuclei. A serological test, the Paul-Bunnell-Davidsohn or heterophil
antibody test is usually positive, though false positive reactions do occur. Fool-
proof diagnosis can now be made by showing certain specific antibodies to EB virus,
and these will be discussed later.
THE ASSOCIATED CANCERS
The two human cancers closely associated with EB virus are Burkitt's lymphoma
and nasopharyngeal carcinoma; the virus was originally found in the former. Mr.
Dennis Burkitt, an Ulsterman and a surgeon, working in Uganda, recognised a jaw
tumour commonly occurring in youngsters, with a peak incidence around five to
seven years of age, and in investigating this he undertook many landrover "Tumour
Safaris" in Uganda and throughout Africa, and made many exciting observations.
He first reported his pioneer work in the Middlesex Hospital Medical School in
London in 1961. There is a restricted geographical distribution of these tumours
with clusters of cases in the area of Africa where malaria is endemic. Sporadic cases
occur in other parts of the world. The histopathology of this lymphoma has a
"starry sky" pattern, due to the large pale macrophages with their abundant
cytoplasm, and the much smaller, closely packed tumour cells, which are B
lymphocytes.
Nasopharyngeal carcinoma occurs primarily in the posterior and lateral walls of
the nasopharynx. With this cancer there is also a restricted geographical distribution,
with a very high incidence in some populations of Chinese descent. In the very high
risk area around Singapore there is a particularly high incidence in the Cantonese
Chinese; this also appears in these Cantonese people who have emigrated to San
Francisco and Hawaii. On the other hand, there is a lower incidence in a number of
countries around the Mediterranean and in East Africa. The peak age of the cancer
is between 45 and 55 years, with males being affected about three times more than
females, and in Tunisia there is an additional age peak of frequency at between ten
and twenty years.
THE VIRUS AND ITS DISCOVERY
Dr. Tony Epstein, a pathologist, at the Middlesex Hospital, became interested in
Burkitt's lymphoma, and in 1964 he and Yvonne Barr, a Dublin Graduate, cultured
cells from tumour material flown from Uganda. Shortly after with Dr. Achong,
another Dublin graduate, they first discovered the virus itself by electron
microscopic examination of the cultured cells. This explains how the virus got its
name-the Epstein-Barr virus.
The virus is divided into three main parts, a central core, a capsid and an
envelope.2 The central core, consists of viral DNA. The capsid, which is icosohedral
in shape, consists of hollow tubular protein sub-units called capsomeres, which are
the "building blocks" which give the virus its shape. The virus acquires its outer
protective coat, or "envelope" from part of the cell in which it grows. All three
parts can be seen microscopically.
While all the other herpesviruses have similar appearance and grow easily in tissue
culture cells used conventionally, EB virus behaves very differently in the laboratory
and is more difficult to propagate.
2METHODS OF STUDYING THE VIRUS
Three main methods are used in the study of this virus. First, cells from African
Burkitt's lymphoma, the B lymphocytes which carry EB virus, can be grown and cell
cultures derived from these have been used in laboratories all over the world as
standard sources ofvirus. Secondly, certain white blood cells, in our circulation, the
B lymphocytes, whose main function is the production of antibody, can be infected
with EB virus. For example, if we take throat washings from a patient with
glandular fever which contain a lot ofvirus at the acute stage ofillness and mix these
washings up with B lymphocytes, the virus will stick to these cells which possess the
appropriate receptors. The protein coat of the virus will be shed and the viral DNA
will be incorporated into the nucleic acid of the B lymphocytes, which will become
"transformed". When this event takes place the cells will proliferate indefinitely
provided they are suitably fed, and we say they are "immortalized". At this stage
each cell contains in its nucleus EB virus nuclear antigen, known as EBNA. Thus,
we use our second method of artifically infecting B lymphocytes either to find out if
an individual is excreting virus, or to measure the amount of virus we are using in
our laboratory tests. In the third method of studying the virus, we estimate the
amount of antibody, and in infections with this particular virus we get maximal
information about the illness if we look for and measure antibody to the different
viral antigens. We do this by means of the immunofluorescent technique, using as
antigen in our tests suitable preparations of standard Burkitt lymphoma cultured
cells showing each particular antigen. Approximately 10 per cent of the cells of the
producer cell line, P3HRI, show capsid antigen, while 100 per cent of the nuclei of
the non-producer line, Raji, contain EBNA. Early antigen is obtained by
superinfecting Raji cells with enveloped virus prepared from cultured P3HRI cells,
and the two types, restricted and diffuse, are obtained by using different fixatives.
We use our antibody tests to determine whether or not individuals have previously
been infected with the virus. The easiest way is to test sera for the presence or
absence of antibody to the viral capsid. While EB virus is extremely common,
serological surveys have shown that primary infection takes place at different ages in
different communities. Most infants in all communities inherit maternal antibody,
which declines rapidly after birth. In East Africa, where Burkitt's lymphoma is
found, by two years of age almost 100 per cent of infants have produced their own
antibody to EB virus as proof of early primary infection. By contrast, in the United
States of America 80 per cent of individuals of a high socio-economic level have
developed antibody only by seventeen years of age. In both these immune groups,
immunity has been acquired by a "silent" or asymptomatic infection. The 20 per
cent who are susceptible in the second group are likely to become infected later, and
about half of those infected experience the clinical illness, glandular fever.
SPECTRA OF ANTIBODIES IN DIFFERENT SITUATIONS
The susceptible individual does not have antibody to any ofthe different antigens,
while the immune individual has antibody in immunoglobulin class G to viral capsid
and also antibody to EBNA. At an early stage of primary infection in childhood,
such as occurs in Uganda, antibody to virus capsid is present in both IgG and IgM
classes, and there is antibody to one component of the early antigen complex, the
restricted component. In glandular fever, again there is antibody to virus capsid in
3both IgG and IgM classes, but the antibody to early antigen is directed against the
diffuse component. Antibody to EBNA develops slowly, while heterophil antibody
is present at an early stage. Very distinctive and different spectra of antibodies exist
in both Burkitt's lymphoma and nasopharyngeal carcinoma. In both conditions
antibodies to capsid antigen in IgG class and EBNA are of high titre, but heterophil
antibody is absent; in Burkitt's lymphoma there is antibody to the restricted
component of the early antigen, while in nasopharyngeal carcinoma the antibody is
to the diffuse component, and antibody to this antigen and to the capsid antigen are
found also in IgA class. Heterophil antibody is not present in either of these
conditions.3
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Figure EB virus antibody response during the course ofglandularfever.
VCA = Virus capsid antigen.
EA = Early antigen.
EBNA = Epstein-Barr nuclear antigen.
The figure shows the sequence of the appearance of antibodies to the different
antigens of EB virus in glandular fever, and it is obvious that the transitory antibody
to early antigen and the transitory antibody to capsid antigen in IgM class are
indicative of active early infection. From the above observations, it is evident how
important detection and measurement of the different antibodies can be in
diagnosis.
PROOF THAT EPSTEIN-BARR VIRUS CAUSES GLANDULAR FEVER
Drs. Gertrude and Werner Henle in Philadelphia showed conclusively that EB
virus causes glandular fever and they did so when they were testing very many sera in
4an attempt to unravel the mystery of the virus found in Burkitt's lymphoma. By a
quite extraordinary coincidence a junior laboratory technician developed glandular
fever and they found that her serum, frozen away in the laboratory some time before
her illness, had no antibodies, while these appeared in her serum during and after
her illness. Confirmation in a large number of patients was possible because stored
samples of serum from Yale University students were available as part of a
prospective clinical and laboratory study ofglandular fever. Also, it was shown that
virus was freely shed from the throat during illness.
Regarding transmission of the virus, interesting studies have shown that a large
and direct inoculum of virus is needed to transmit the disease-indeed, intimate oral
contact labelled the virus "The Kissing Virus". The illness is characteristically
associated with kissing in young adults and affects the more susceptible upper socio-
economic classes. Indeed, a peak incidence in late winter, four-six weeks after
Christmas, with probable increased intimate exposure to virus-containing saliva at
that time has been reported.
This is well illustrated from an article by Dr. Robert J. Hoagland in the American
Journal of Medical Sciences, 1955.4 I quote: "One of my patients with infectious
mononucleosis stated that on December 23, 1950, he was in a train and spent about
twelve hours in the company of a female medical student whom he had never seen
before and whom he never saw again, but with whom he corresponded. These two
individuals kissed frequently and, more important, in a way to allow mingling of
saliva ... The patient learned, by letter, from his train acquaintance, that she was a
patient in a university hospital with a disease diagnosed as infectious mononu-
cleosis". This story speaks for itself.
RELATIONSHIP OF EPSTEIN-BARR VIRUS TO BURKITT'S LYMPHOMA
AND NASOPHARYNGEAL CARCINOMA
Extensive and difficult investigations have not proved conclusively that Epstein-
Barr virus is the sole cause of Burkitt's lymphoma and nasopharyngeal carcinoma.
First I shall discuss findings in relation to the 98 per cent of cases of Burkitt's
lymphoma which contain virus and which occur in the high incidence area in Africa.
The proof of the virus association in endemic Burkitt's lymphoma is-firstly, that
there is a very "special" spectrum of antibodies of a very high titre, and the
antibody to the early antigen complex points to active ongoing viral activity.
Secondly, after surgery or chemotherapy, a drop in antibody indicates a favourable
prognosis, whereas a rise in antibody points to tumour recurrences. Thirdly, cells
from the tumour can be grown in culture outside the body and are what we call
monoclonal: that is, growth occurs from the multiplication ofa single cell. Fourthly,
the virus from the tumour itself has the ability to "transform" B lymphocytes and
the molecular biologists have been able to show us that Epstein-Barr virus DNA is in
each tumour cell, as well as EBNA. When the tumour cells are injected into New
World monkeys they cause tumours.
A rather similar set of findings occurs in nasopharyngeal carcinoma. There is a
distinctive pattern of antibodies of high titre-with specific antibody in immuno-
globulin class A-probably locally stimulated in the pharynx. Further, a rise in
antibody has been shown to be associated with increased tumour size and with
5secondaries-a fall occurs with successful treatment. Viral DNA and EBNA have
been shown in the epithelial carcinomatous cells in all classical cases of nasopharyn-
geal carcinoma, and while these cells have not been cultured outside the body, it has
been possible to transform B lymphocytes with virus particles from the tumours.
In summary, very high levels of antibody to EB virus occur in both Burkitt's
lymphoma and nasopharyngeal carcinoma, multiple copies of viral DNA occur in
both tumours and in the case of Burkitt's lymphoma whose cells can be cultured, the
tumour is monoclonal. Distinct differences exist between the cultured cells of
Burkitt's lymphoma and cultured B lymphocytes from healthy individuals
previously infected with EB virus, whose cells will grow due to reactivation of latent
virus. In Burkitt's lymphoma the tumour cells are monoclonal, while cultured cells
from a healthy person are polyclonal, several clones of cells having multiplied. The
lymphoma cells are aneuploid with the chromosomal marker 14q+, while the healthy
cells are diploid and do not possess a special chromosomal marker. The lymphoma
cells have the ability to induce tumours when injected into certain monkeys, while
the healthy cells will not. There are different surface glycoproteins on the two cell
types.l.
While Burkitt's lymphoma is a monoclonal tumour with Epstein-Barr virus in
every cell indicating that the original B lymphocyte undergoing malignant
transformation must have been infected at the outset, nasopharyngeal carcinoma is
the proliferation ofa clone ofcarcinomatous epithelial cells, containing EB virus. In
both conditions the serological profile is consistent with patients carrying a heavy
load of the virus.
But it is difficult to reconcile the ubiquitous presence ofthe virus with the rarity of
these tumours. A prospective study of sera from 42,000 children in Uganda showed
that normal patterns of antibody to EB virus were present long before the develop-
ment of the tumour; in other words the children had their primary viral infection
before the tumour began to grow.6 It has been argued that malaria is the crucial co-
factor which triggers off the malignancy, and a clear parallel has been shown
between a high incidence of Burkitt's lymphoma, a high level of malarial infection
and, to a lesser degree, high temperature and high rainfall. Evidence points to the
EB virus infecting infants in the neo-natal period when the lymphocytes and indeed
the entire immune system is immature, while heavy malarial burden and possibly
other environmental and host factors are also involved in the pathogenesis of
Burkitt's lymphoma. The fact that malaria infection has recently been shown to
stimulate the growth and proliferation of B lymphocytes, and also to suppress T
lymphocytes, the regulatory cells which control the immune responses of the body,7
supports the view that environmental factors are closely implicated.
In areas where nasopharyngeal carcinoma occurs it has been shown that primary
EB virus infection also occurs very early in life, and again the long interval between
virus infection and tumour development suggest participation of co-factors. In
South East Asia persons affected are usually over 40 years. Multiple cases, with a
preponderance in males, occur in Chinese families through several generations, and
a certain histocompatibility antigen has been found in high frequency in these Asian
cases. Indeed this antigen appears to be a marker for a very high risk of developing
nasopharyngeal carcinoma. This would point to the importance ofgenetic factors in
the pathogenesis of this cancer, though there may also be environmental cases. For
6instance, consumption by Cantonese Chinese of salted fish, known to contain a
carcinogenic compound, may precipitate the cancer.
Thus, there is strong evidence that EB virus is a causative factor in these two
human cancers. Professor Epstein believes that the perfecting of a preventative
vaccine, and its subsequent use, will give the final answer as to whether or not EB
virus is a cause in both ofthe conditions. Regarding Burkitt's lymphoma-many pin
their faith in the successful eradication of malaria, to eliminate the tumour.
What are we to say about anti-viral drugs in this respect? Undoubtedly the new
anti-viral agent Acyclovir or acycloguanosine,8 has attracted much attention in
relation to the herpesvirus group. Clinicians have been most enthusiastic in its
preliminary use, for instance in shingles in immunosuppressed patients, in whom it
is being carefully evaluated. However, it has been shown that EB virus is only very
slightly sensitive to this drug, so it looks as if we will have to wait for another anti-
viral drug to turn up to cope with this virus.
IMMUNOLOGICAL ASPECTS OF EPSTEIN-BARR VIRUS INFECTION
Immunologists have learnt a lot about how the immune system works by
examining both antibodies to EB virus, and also the reactions of the cells of the
immune system, both in patients with infectious mononucleosis, and also in patients
with a wide variety of disorders of the immune system.
In a healthy immune person, neutralising antibodies will block any further
infecting virus from infecting a B lymphocyte. If a virus does pass this block and
infect such a cell, suppressor T lymphocytes will prevent the B lymphocyte from
transforming. If any B lymphocyte does transform, it will be prevented from
proliferating by further suppression by T lymphocytes.
However, if a susceptible adult does become infected, these first three
mechanisms may be insufficient to stop proliferation of the B cells, now
EBNA-positive from growing; therefore the more powerful killer T cells come into
play. This is what happens in infectious mononucleosis. Indeed the majority of the
atypical lymphocytes in the blood of patients with infectious mononucleosis are T
cells of different types-some are probably cytotoxic, some are suppressor, and
others are immature T cells.9 George Klein describes infectious mononucleosis as a
"Civil War" between a small number ofvirus-transformed cells, and a large number
ofT cells.10. Most primary infections are not manifested as infectious mononucleosis
-in children and in subclinical infection, infection is controlled without the large
scale T cell response, seen in infectious mononucleosis.
The patient recovers after infection and the virus establishes itself in a persistent
carrier state. When the lymphocytes are cultured the virus can be recovered
indefinitely, and in addition the virus is shed intermittently into the saliva. However,
in immunosuppressed patients, such as patients following renal transplant, virus is
shed much more freely."* One immunosuppressive agent, Cyclosporin A, has been
shown to inhibit the controlling effect of the T cells, and thus causes B cell
lymphomas containing EB virus.'2 Such lymphomas and also widespread growth of
virus have been found in rare instances where there is a loss of immunoregulatory
control, or a cytogenetic defect in B cells.'3
7Raised antibody titres to EB virus have been found in disease like sarcoidosis and
systemic lupus erythematosus,14. which have in themselves an immunosuppressive
effect, and it is well documented that those Hodgkin's disease patients, who have
very high levels of antibody to EB virus,'5 have depressed cell mediated immunity,
or lack of control of antibody production due to failure of suppressor T cells.
Recent findings in this and in other situations have prompted the suggestion that
"patterns" of antibody to EB virus might be a more sensitive measure of defective
cell mediated immunity than more conventional tests of immune function. 16.
SUMMARY
I have given a panoramic view of the EB virus and the diseases associated with
it. On the one hand the virus has been shown to cause the infectious disease,
infectious mononucleosis-on the other hand it has been shown to be closely
associated with two human cancers of two distinct cell types, B lymphocytes in
Burkitt's lymphoma, and epithelial cells in nasopharyngeal carcinoma. This virus
persists harmlessly in the vast majority ofindividuals. However, it is now recognised
that undesired effects of the virus are connected with alterations of the immune
system; some of these have a genetic origin, and some result from immuno-
suppressive therapy now frequently employed. Therefore I believe firmly that this
virus has to be reckoned with, and indeed has to be considered as a candidate virus
which may be involved in pathogenesis in a wide variety of diseases of unknown
aetiology.
The remarkable story of this virus will continue, and we can understand
Roizman's comment: "Not since the heyday of poliomyelitis research has a single
agent attracted so much interest as Epstein-Barr virus"."'
REFERENCES
I Epstein MA, Achong BG. Introduction: discovery and general biology of the virus. In: Epstein MA,
Achong BG, eds. The Epstein-Barr virus. Berlin. Heidelberg. New York: Springer-Verlag, 1979:
1-4.
2 De-The G, Lenoir G. Comparative diagnosis of Epstein-Barr virus-related diseases: infectious
mononucleosis, Burkitt's lymphoma, and nasopharyngeal carcinoma. In: Kurstak E, Kurstak C,
eds. Comparative diagnosis ofviraldisease, vol. 1. New York. San Francisco. London: Academic
Press, 1977: 198.
3 Henle W, Henle G, Lennette ET. The Epstein-Barr virus. Scientific American 1980; 241: 40-51.
4 Hoagland RJ. The transmission of infectious mononucleosis. Am J Med Sci 1955; 229: 262-72.
5 Nilsson K. The nature of lymphoid cell lines and their relationship to the virus. In: Epstein MA,
Achong BG, eds. The Epstein-Barr virus. Berlin. Heidelberg. New York: Springer-Verlag, 1979:
229.
6 De-The G. Demographic studies implicating the virus in the causation of Burkitt's lymphoma:
Prospects for nasopharyngeal carcinoma. In: Epstein MA, Achong BG, eds. The Epstein-Barr
virus. Berlin. Heidelberg. New York: Springer-Verlag, 1979: 417-37.
7 Schwartz RS. Epstein-Barr virus-oncogen or mitogen? NEngI J Med 1980; 302: 1307-8.
8 Finter NB. Personal communication 1980.
9 Thorley-Lawson DA. The suppression of Epstein-Barr virus infection in vitro occurs after infection
but before transformation of the cell. J Immunol 1980; 124: 745-51.
10 Klein G. EBV-persistence in human lymphoid and carcinoma cells. In: Stevens JG, Todaro GJ,
Fox CF, eds. Persistent Viruse:. New York. San Francisco. London: Academic Press, 1978: 27-42.
11 Strauch B, Andrews LL, Siegel N, Millar G. Oropharyngeal excretion of Epstein-Barr virus by renal
transplant recipients and other patients treated with immunosuppressive drugs. Lancet 1974; 1:
234-7.
812 Crawford DH, Thomas JA, Janossy G, et al. Epstein-Barr virus nuclear antigen positive lymphoma
after cyclosporin A treatment in patient with renal allograft. Lancet 1980; 1: 1355-6.
13 Purtilo DT. Epstein-Barr virus-induced oncogenesis in immune-deficient individuals. Lancet 1980:
1: 300-3.
14 Evans AS, Rothfield NF, Niederman JC. Raised antibody titres to E.B. virus in systemic lupus
erythematosus. Lancet 1971; 1: 167-8.
15 Henle W, Henle G. Epstein-Barr virus-related serology in Hodgkin's disease. In: Kaplain HS, ed.
National Cancer Institute Monograph No 36. 1973; 79-84.
16 Lange B, Henle W, Meyers JD, et al. Epstein-Barr virus-related serology in marrow transplant
recipients. Int J Cancer 1980; 26: 151-7.
17 Roizman B. Aspects of Epstein-Barr virus. Cell 1980; 19: 562-3.
9